Experimental models of Huntington's disease;Modelos experimentales de la enfermedad de Huntington

Revista de Neurologia

Volumn 45, Issue 7, 2007, Pages 437-441

  García Ramos, Rocío ^a   Del Val Fernandez J ^a   Catalan Alonso M J ^a   Barcia Albacar, J A ^a   Matias Guiu J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

3 nitropropionic acid; Cellular models; Excitotoxic models; Huntington's disease; Quinolinic acid; Transgenic mice

Indexed keywords

3 NITROPROPIONIC ACID; PRION PROTEIN;

CELL CULTURE; COGNITION; EXCITOTOXICITY; EXPERIMENTAL MODEL; FLY; HUNTINGTON CHOREA; KNOCKOUT GENE; MAZE TEST; MEDICAL RESEARCH; MEDLINE; MOTOR PERFORMANCE; NONHUMAN; PROMOTER REGION; REVIEW; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; YEAST ARTIFICIAL CHROMOSOME;

EID: 37349079897     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4507.2007238     Document Type: Review

References (20)

1. Walker FO. Huntington's disease. Lancet 2007; 369: 218-28.
2. McMurray CT. Huntington's disease: new hope for therapeutics. Trends Neurosci 2001; 24: 32-8.
3. Chu-LaGraff Q, Kang XW, Messer A. Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice. Brain Res Bull 2001; 56: 307-12.
4. Rubinsztein DC. Lessons from animal models of Huntington's disease. Trends Genet 2002; 18: 202-9.
5. Li JY, Popovic N, Brundin P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005; 2: 447-64.
6. Menalled LB, Chesselet MF. Mouse models of Huntington's disease. Trends Pharmacol Sci 2002; 23: 32-9.
7. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101: 57-66.
8. Tanaka Y, Igarashi S, Nakamura M, Gafni J, Torcassi C, Schilling G, et al. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol Dis 2006; 21: 381-91.
9. Petrasch-Parwez E, Nguyen HP, Bbecke-Schumacher ML, Habbes HW, Wieczorek S, Riess O, et al. Cellular and subcellular localization of Huntington aggregates in the brain of a rat transgenic for Huntington disease. J Comp Neurol 2007; 501: 716-30.
10. Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1217-40.
11. Francis L, Cruz R, Antúnez I, Rosillo JC. Behavior characterization of a model of Huntington's disease in rats, induced by quinolinic acid. Rev Neurol 2000; 30: 1016-21.
12. Blum D, Galas MC, Gall D, Cuvelier L, Schiffmann SN. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol Dis 2002; 10: 410-26.
13. Brouillet E, Conde F, Beal MF, Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 1999; 59: 427-68.
14. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997; 79: 45-56.
15. Marsh JL, Pallos J, Thompson LM. Fly models of Huntington's disease. Hum Mol Genet 2003; 15: 187-93.
16. Lievens JC, Rival T, Iche M, Chneiweiss H, Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 2005; 14: 713-24.
17. Marsh JL, Pallos J, Thompson LM. Fly models of Huntington's disease. Hum Mol Genet 2003; 12: 187-93.
18. Piconi B, Pasión E, Sgobio C, Bonsi P, Barone I, Ghigliori V, et al. Plastic and behavioural abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 2006; 22: 143-52.
19. Canal JM, Pineda JR, Torres-Peraza JF, Bosch M, Martín- Ibáñez R, Muñoz MT, et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 2004; 24: 7727-39.
20. Lunkes A, Mandel JL. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 1998; 7: 1355-61.